COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,677 Articles (22,913 medRxiv, 8,764 bioRxiv)

Most recent first Previous |  Page 1670: Articles 16691-16700  | Next

Development of a tool to prioritize the monitoring of COVID-19 patients by public health teams
Vecino-Ortiz, A. I., Guzman-Tordecilla, N., Guzman Ruiz, Y. F., Penaloza-Quintero, R. E., Fernandez-Nino, J. A., Ruiz Gomez, F., Trujillo, A. J.
10.1101/2021.04.08.21254922 — Posted: 2021-04-11
Changing patterns of sickness absence among healthcare workers in England during the COVID-19 pandemic.
Edge, R., van der Plaat, D. A., Parsons, V., Coggon, D., van Tongeren, M. J., Muiry, R., Madan, I., Cullinan, P.
10.1101/2021.04.08.21255128 — Posted: 2021-04-10
Estimating COVID-19 infection fatality rate in Mumbai during 2020
Banaji, M.
10.1101/2021.04.08.21255101 — Posted: 2021-04-10
Early evidence of COVID-19 vaccine effectiveness within the general population of California
Andrejko, K., Pry, J. M., Myers, J. F., Jewell, N. P., Openshaw, J., Watt, J., Jain, S., Lewnard, J. A.
10.1101/2021.04.08.21255135 — Posted: 2021-04-10
Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States
Rainwater-Lovett, K., Redd, J. T., Stewart, M. A., Elias Calles, N., Cluff, T., Fang, M., Panaggio, M. J., Lambrou, A. S., Thornhill, J. K., Bradburne, C., Imbriale, S., Freeman, J. D., Anderson, M., Kadlec, R. P.
10.1101/2021.04.08.21254705 — Posted: 2021-04-10
Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Convalescent Plasma Hesitancy cost lives?
Casadevall, A., Dragotakes, Q., Johnson, P. W., Senefeld, J. W., Klassen, S. S., Wright, S. R., Joyner, M. J., Paneth, N., Carter, R.
10.1101/2021.04.07.21255089 — Posted: 2021-04-10
Modelling the impact of extending dose intervals for COVID-19 vaccines in Canada
Nam, A., Ximenes, R., Yeung, M. W., Mishra, S., Wu, J., Tunis, M., Sander, B.
10.1101/2021.04.07.21255094 — Posted: 2021-04-10
Direct and indirect effectiveness of mRNA vaccination against SARS-CoV-2 infection in long-term care facilities in Spain
Monge, S., Olmedo, C., Alejos, B., Lapena, M., Sierra, M. J., Limia, A.
10.1101/2021.04.08.21255055 — Posted: 2021-04-10 Discussion: Onsite
Bead-assisted SARS-CoV-2 multi-antigen serological test allows effective identification of patients
Caceres-Martell, Y., Fernandez-Soto, D., Campos-Silva, C., Garcia-Cuesta, E. M., Casasnovas, J. M., Navas-Herrera, D., Beneitez-Martinez, A., Martinez-Fleta, P., Alfranca, A., Sanchez-Madrid, F., Escudero-Lopez, G., Vilches, C., Jara-Acevedo, R., Reyburn, H. T., Rodriguez-Frade, J. M., Vales-Gomez, M.
10.1101/2021.04.08.21254348 — Posted: 2021-04-10
Impact of the COVID-19 pandemic and response on the utilisation of health services during the first wave in Kinshasa, the Democratic Republic of the Congo
Hategeka, C., Carter, S. E., Chenge, F. M., Katanga, E. N., Lurton, G., Mayaka, S. M.-N., Mwamba, D. K., van Kleef, E., Vanlerberghe, V., Grepin, K. A.
10.1101/2021.04.08.21255096 — Posted: 2021-04-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).